Your browser doesn't support javascript.
loading
Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells.
Morris, Vivian; Wang, Dahai; Li, Zhiheng; Marion, William; Hughes, Travis; Sousa, Patricia; Harada, Taku; Sui, Shannan Ho; Naumenko, Sergey; Kalfon, Jérémie; Sensharma, Prerana; Falchetti, Marcelo; Vinicius da Silva, Renan; Candelli, Tito; Schneider, Pauline; Margaritis, Thanasis; Holstege, Frank C P; Pikman, Yana; Harris, Marian; Stam, Ronald W; Orkin, Stuart H; Koehler, Angela N; Shalek, Alex K; North, Trista E; Pimkin, Maxim; Daley, George Q; Lummertz da Rocha, Edroaldo; Rowe, R Grant.
Afiliação
  • Morris V; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Wang D; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Li Z; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Marion W; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Hughes T; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Sousa P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Harada T; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA.
  • Sui SH; Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Naumenko S; Harvard Chan Bioinformatics Core, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Kalfon J; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Sensharma P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Falchetti M; Graduate Program of Pharmacology, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.
  • Vinicius da Silva R; Graduate Program of Pharmacology, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.
  • Candelli T; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Schneider P; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Margaritis T; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Holstege FCP; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Pikman Y; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA.
  • Harris M; Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Stam RW; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Orkin SH; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA.
  • Koehler AN; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Shalek AK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Institute for Medical Engineering & Science, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, M
  • North TE; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Pimkin M; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02115, USA.
  • Daley GQ; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Lummertz da Rocha E; Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis Santa Catarina 88040-900, Brazil.
  • Rowe RG; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Stem Cell Transplantation Program, Department of Hematology, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Bos
Cell Rep ; 39(4): 110752, 2022 04 26.
Article em En | MEDLINE | ID: mdl-35476984
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos